[ Skip to main content ]
This article is over 3 years old

The passing of world leading legislation on new psychoactive substances takes New Zealand a big step closer to healthy drug law, the New Zealand Drug Foundation said today.

“The Psychoactive Substances Act is a world first at getting ahead of the ‘legal highs’ industry and taking control of the problems these substances cause,” New Zealand Drug Foundation Executive Director Ross Bell said.

The law, which passed its final reading in Parliament today, sets up a regulatory framework where manufacturers of products like synthetic cannabis will have to prove they are ‘low risk’ before the can be sold. It also imposes restrictions on who can make and sell the substances as well as measures to reduce availability.

“This is a cutting edge and pragmatic approach to new psychoactive substances which will reduce the harm they cause in our communities,” Mr Bell said.

“It is fantastic that the Government has listened to community concerns, acted on the evidence and built consensus on the best way to handle this complicated area of policy.”

Mr Bell said that the regulation of new psychoactive substances was the first step in the right direction for healthy drug law.

“New Zealand now needs to implement broader health-focussed changes to our outdated drug laws.”

The Psychoactive Substances Act key points

  • Sets up a legal framework for the testing, manufacture, sale and regulation of psychoactive products.
  • Includes health and harm minimisation in the purpose of the act.
  • Products will no longer be sold in dairies, grocery stores etc. People and businesses will need a license to sell the products.
  • Restrictions on advertising and marketing and the purchase age (18+)
  • Like alcohol, councils will have the option of developing local policies around where stores can be located.
  • Products will undergo rigorous clinical testing to determine whether they are ‘low risk’.
  • Clear rules around use of animal testing. Animal testing can only be used if there is no alternative.
  • If proven a product is ‘low risk’ of harm then as long as a person meets certain criteria (e.g. person of good repute, NZ citizen) a three year licence to sell that product can be granted.
  • Products which appear to cause more harm than clinical testing showed can be pulled from the market.
  • A register of all approved and unapproved products will be publically available.
  • A code of practice will be in place within 6 months.
This article is over 3 years old
Share this article:
Share:

Related See more

michael dPb5qrbsWtA unsplash2

What can we learn from Canberra decriminalising drug possession?

Commentator Russell Brown takes a look at the ACT's road to decriminalising drug possession, and asks what New Zealand could learn.

20220830 161419

Street value: The Dutch MDMA pop-up shop sparking conversations about drugs

Drug Foundation Communications Advisor Feilidh Dwyer visits a thought-provoking MDMA pop-up shop in Utrecht.

cannabis oil

Harm reduction tips for medicinal cannabis users

Too many kiwis are still buying medicinal cannabis on the black market. We asked two leading experts for some harm reduction tips to keep th...

iStock 861044728 v4

What happened in Wairarapa could happen again

Drug Foundation executive director Sarah Helm discusses recent fentanyl overdoses in Wairarapa and how we can avoid fentanyl deaths in futur...

The Level promo

Straight up guide for people who use drugs

The Level is for real people, in real life, whatever level they are at.

The Level

social graphic subscribe

Subscribe to email updates

Get regular news, analysis and commentary on drug issues in New Zealand. Free.

Sign up now!

Back to top